Tachyphylaxis after Repeated Antidepressant Drug Exposure in Patients with Recurrent Major Depressive Disorder

被引:30
|
作者
Amsterdam, Jay D. [1 ]
Williams, David [2 ]
Michelson, David [3 ]
Adler, Lenard A. [4 ]
Dunner, David L. [5 ]
Nierenberg, Andrew A. [6 ]
Reimherr, Frederick W. [7 ]
Schatzberg, Alan F. [8 ]
机构
[1] Univ Penn, Sch Med, Dept Psychiat, Depress Res Unit,Univ Sci Ctr, Philadelphia, PA 19104 USA
[2] Eli Lilly & Co, Lilly Res Labs, Indianapolis, IN 46285 USA
[3] Merck & Co Inc, Merck Res Labs, Rahway, NJ 07065 USA
[4] NYU, Dept Psychiat, New York, NY 10016 USA
[5] Ctr Anxiety & Depress, Mercer Isl, WA USA
[6] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Depress Clin & Res Program,Dept Psychiat, Boston, MA USA
[7] Univ Utah, Hlth Sci Ctr, Dept Psychiat, Mood Disorders Clin, Salt Lake City, UT USA
[8] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA
关键词
Tachyphylaxis; Treatment resistant depression; Antidepressant drug therapy; Serotonin reuptake inhibitor; Major depressive disorder; SEROTONIN TRANSPORTER GENE; TREATMENT-RESISTANT DEPRESSION; STAR-ASTERISK-D; LONG-TERM TREATMENT; REUPTAKE INHIBITORS; ALLELIC VARIATION; VENLAFAXINE; EFFICACY; POLYMORPHISM; MIRTAZAPINE;
D O I
10.1159/000226611
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: The aim of this post hoc analysis was to examine whether tachyphylaxis occurs after repeated courses of antidepressant drug therapy. Method: 276 patients with major depressive disorder (MDD) were treated with sertraline (150-200 mg daily) for 8 weeks. Patients with persistent MDD after sertraline therapy were randomized to continuation therapy with either sertraline plus atomoxetine (n = 72) or sertraline plus placebo (n = 74) for 8 additional weeks. Logistic regression was used to test the hypothesis that an increase in prior antidepressant drug exposure is associated with a reduced responsiveness to sertraline therapy. Results: The number of prior antidepressant drug exposures was negatively associated with response to initial sertraline therapy (odds ratio = 0.81, p = 0.0035). The odds ratio indicates a 19.9% reduced likelihood of response with each prior antidepressant treatment trial. In contrast, the number of prior antidepressant treatment trials was not associated with response to continuation sertraline plus atomoxetine or sertraline plus placebo therapy. Conclusion: This observation supports the hypothesis that tachyphylaxis may develop after repeated antidepressant drug trials. Copyright (C) 2009 S. Karger AG, Basel
引用
收藏
页码:227 / 233
页数:7
相关论文
共 50 条
  • [31] Efficacy of adjunctive aripiprazole in patients with major depressive disorder who showed minimal response to initial antidepressant therapy
    Nelson, James Craig
    Thase, Michael E.
    Bellocchio, Elizabeth E.
    Rollin, Linda M.
    Eudicone, James M.
    McQuade, Robert D.
    Marcus, Ronald N.
    Berman, Robert M.
    Baker, Ross A.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2012, 27 (03) : 125 - 133
  • [32] ARPNet: Antidepressant Response Prediction Network for Major Depressive Disorder
    Chang, Buru
    Choi, Yonghwa
    Jeon, Minji
    Lee, Junhyun
    Han, Kyu-Man
    Kim, Aram
    Ham, Byung-Joo
    Kang, Jaewoo
    GENES, 2019, 10 (11)
  • [33] Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder
    Albott, C. Sophia
    Lim, Kelvin O.
    Erbes, Christopher
    Thuras, Paul
    Wels, Joseph
    Tye, Susanna J.
    Shiroma, Paulo R.
    JOURNAL OF AFFECTIVE DISORDERS, 2022, 308 : 289 - 297
  • [34] Sexual Functioning in Patients With Recurrent Major Depressive Disorder Enrolled in the PREVENT Study
    Gelenberg, Alan J.
    Dunner, David L.
    Rothschild, Anthony J.
    Pedersen, Ron
    Dorries, Kathleen M.
    Ninan, Philip T.
    JOURNAL OF NERVOUS AND MENTAL DISEASE, 2013, 201 (04) : 266 - 273
  • [35] Neurocognitive performance and repeated-dose intravenous ketamine in major depressive disorder
    Zheng, Wei
    Zhou, Yan-Ling
    Liu, Wei-Jian
    Wang, Cheng-Yu
    Zhan, Yan-Ni
    Li, Han-Qiu
    Chen, Li-Jian
    Li, Ming-D
    Ning, Yu-Ping
    JOURNAL OF AFFECTIVE DISORDERS, 2019, 246 : 241 - 247
  • [36] Levomilnacipran: a newly approved drug for treatment of major depressive disorder
    Mago, Rajnish
    Mahajan, Rajeev
    Thase, Michael E.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2014, 7 (02) : 137 - 145
  • [37] Tumor Necrosis Factor-α Variations in Patients With Major Depressive Disorder Before and After Antidepressant Treatment
    Yao, Lin
    Pan, LiHong
    Qian, Min
    Sun, Wei
    Gu, ChunHong
    Chen, LiangHu
    Tang, XiaoChen
    Hu, YeGang
    Xu, LiHua
    Wei, YanYan
    Hui, Li
    Liu, XiaoHua
    Wang, JiJun
    Zhang, TianHong
    FRONTIERS IN PSYCHIATRY, 2020, 11
  • [38] Acute working memory improvement after tDCS in antidepressant-free patients with major depressive disorder
    Oliveira, Janaina F.
    Zanao, Tamires A.
    Valiengo, Leandro
    Lotufo, Paulo A.
    Bensenor, Isabela M.
    Fregni, Felipe
    Brunoni, Andre R.
    NEUROSCIENCE LETTERS, 2013, 537 : 60 - 64
  • [39] Recovery and subsequent recurrence in patients with recurrent major depressive disorder
    Dunlop, Boadie W.
    Holland, Peter
    Bao, Weihang
    Ninan, Philip T.
    Keller, Martin B.
    JOURNAL OF PSYCHIATRIC RESEARCH, 2012, 46 (06) : 708 - 715
  • [40] Repetitive transcranial magnetic stimulation may be a cost-effective alternative to antidepressant therapy after two treatment failures in patients with major depressive disorder
    Antal Zemplényi
    Judit Józwiak-Hagymásy
    Sándor Kovács
    Dalma Erdősi
    Imre Boncz
    Tamás Tényi
    Péter Osváth
    Viktor Voros
    BMC Psychiatry, 22